Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 4Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 2Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × naporafenib × Clear all
NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Novartis

Phase 1 Terminated
122 enrolled
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT02607813 2022-12-21

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Novartis

Phase 1 Terminated
142 enrolled
DermatologicGynecologic

Melanoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡